Panacea Biotec shares jumped 9.3 per cent on BSE, logging an intra-day high at ₹418.35 per share. The buying on the counter ...

The shares of Panacea Biotec touched its 52-week high of ₹581 on May 15, 2025, and a 52-week low of ₹282.15 on February 28, ...

Panacea Biotec share price jumps nearly 14% after Unicef increases vaccine order value for 2026-27, boosting investor ...

At the Panacea Biotec office, conversations around DengiAll are cloaked with an air of eagerness. With the human trials ...

DengiAll emerges as a promising single-dose solution offering balanced protection against all four dengue types.

After nearly two decades of research, India’s first dengue vaccine, DengiAll, is ready to make its mark. Designed to fight ...

The company said a total of 10,335 participants have been enrolled in the late stage trial. Each participant will be ...

Panacea Biotec completes Phase III enrolment for DengiAll®, India's first indigenous dengue vaccine, with 10335 participants ...

With a market capitalisation of Rs 2,534 crore, the shares of Panacea Biotec Ltd reached a day’s high of Rs 422.30 per share, up 9 percent from its previous day’s closing price of Rs 383.70 per share.

Panacea Bio share price has gained 7.27% in the past five sessions and nearly 21% in a month. However, the scrip has declined ...

Three Pharma stocks, Panacea Biotec, Sun Pharma, and Strides Pharma, are in the spotlight for notable developments this ...

Shares of Panacea Biotec Ltd hit a 5 percent upper circuit after its board approved selling of pharmaceutical formulation brands of its arm to Mankind Pharma Ltd. The stock of the vaccine manufacturer ...